文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

巴氯芬与慢性肾脏病患者脑病的关联

Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease.
PubMed 文献 · JAMA · 2019-01-01
一句话结论慢性肾脏病老年患者新处方巴氯芬≥20 mg/d相比<20 mg/d,30天脑病住院风险增加约3.5倍,且eGFR越低绝对风险越高。

这项基于加拿大安大略省2007-2018年链接医疗数据的回顾性人群队列研究,纳入15942例≥66岁、eGFR<60 mL/min/1.73 m²且未透析的慢性肾脏病患者,比较新处方口服巴氯芬≥20 mg/d与<20 mg/d的30天脑病住院风险。结果显示,高剂量组脑病住院108/9707(1.11%),低剂量组26/6235(0.42%),加权RR 3.54(95%CI 2.24-5.59),加权RD 0.80%(95%CI 0.55%-1.04%)。亚组分析显示eGFR越低绝对风险越高,eGFR<30组加权RD 2.90%(95%CI 1.30%-4.49%)。与284263例非使用者相比,巴氯芬使用者脑病风险更高(<20 mg/d加权RR 5.90,≥20 mg/d加权RR 19.8)。作者认为若这些风险被验证,应与巴氯芬的获益相权衡。

要点

  • 慢性肾脏病老年患者新处方巴氯芬≥20 mg/d vs <20 mg/d,30天脑病住院加权RR 3.54(95%CI 2.24-5.59),加权RD 0.80%(95%CI 0.55%-1.04%)。
  • eGFR越低,巴氯芬相关脑病绝对风险越高:eGFR 45-59加权RD 0.42%,eGFR 30-44为1.23%,eGFR<30为2.90%(交互P<.001)。
  • 与非使用者(284263例)相比,巴氯芬<20 mg/d使用者脑病加权RR 5.90(95%CI 3.59-9.70),≥20 mg/d使用者加权RR 19.8(95%CI 14.0-28.0)。
  • 脑病定义为开始巴氯芬后30天内因谵妄、定向障碍、短暂意识改变、短暂性脑缺血发作或未特指痴呆主诊断住院。
  • 作者认为若这些风险被验证,应与巴氯芬的获益相权衡。

适用人群与场景

  • 纳入:加拿大安大略省2007-2018年≥66岁、eGFR<60 mL/min/1.73 m²且未接受透析的慢性肾脏病患者。
  • 主要队列:新处方口服巴氯芬者;次要队列:新使用者与非使用者。
  • 排除:接受透析的患者(原文以未接受透析定义CKD人群)。

诊断标准与关键阈值

  • 慢性肾脏病定义:eGFR<60 mL/min/1.73 m²且未接受透析。
  • 主要结局脑病定义:开始巴氯芬后30天内因谵妄、定向障碍、短暂意识改变、短暂性脑缺血发作或未特指痴呆主诊断住院。
  • 暴露分组阈值:口服巴氯芬≥20 mg/d vs <20 mg/d。

研究设计与关键结果

  • 研究类型:回顾性人群队列研究,基于加拿大安大略省2007-2018年链接医疗数据,采用倾向评分逆概率治疗加权。
  • 主要队列15942例(9699例[61%]女性;中位年龄77岁[IQR 71-82]),其中9707例(61%)起始巴氯芬≥20 mg/d、6235例(39%)<20 mg/d。
  • 主要终点脑病住院:≥20 mg/d组108/9707(1.11%)vs <20 mg/d组26/6235(0.42%),加权RR 3.54(95%CI 2.24-5.59),加权RD 0.80%(95%CI 0.55%-1.04%)。
  • 亚组绝对风险随eGFR降低而递增:eGFR 45-59加权RD 0.42%(95%CI 0.19%-0.64%);eGFR 30-44加权RD 1.23%(95%CI 0.62%-1.84%);eGFR<30加权RD 2.90%(95%CI 1.30%-4.49%);交互P<.001。
  • 次要比较(非使用者284263例):巴氯芬<20 mg/d加权RR 5.90(95%CI 3.59-9.70),≥20 mg/d加权RR 19.8(95%CI 14.0-28.0)。

证据类型、等级与局限

  • 证据类型:回顾性人群队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对≥66岁、eGFR<60 mL/min/1.73 m²且未透析的慢性肾脏病患者新处方巴氯芬时,处方≥20 mg/d者30天脑病住院风险高于<20 mg/d者(加权RR 3.54),eGFR<30者绝对风险增加最明显(加权RD 2.90%)。
  • 与非使用者相比,巴氯芬<20 mg/d和≥20 mg/d使用者的脑病风险均更高(加权RR分别为5.90和19.8)。
  • 作者认为若这些风险被验证,应与巴氯芬的获益相权衡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidney disease (CKD).

OBJECTIVE: To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective population-based cohort study in Ontario, Canada (2007-2018) using linked health care data. Participants comprised 15 942 older adults (aged 66 years or older) with CKD (defined as an estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 but not receiving dialysis). The primary cohort was restricted to patients who were newly prescribed baclofen; participants in the secondary cohort were new users and nonusers.

EXPOSURES: Prescription for oral baclofen greater than or equal to 20 mg per day vs less than 20 mg per day.

MAIN OUTCOMES AND MEASURES: Hospital admission with encephalopathy, defined as a main diagnosis of delirium, disorientation, transient alteration of awareness, transient cerebral ischemic attack, or unspecified dementia within 30 days of starting baclofen. Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on indicators of baseline health. Weighted risk ratios (RRs) were obtained using modified Poisson regression and weighted risk differences (RDs) using binomial regression. Prespecified subgroup analyses were conducted by eGFR category.

RESULTS: The primary cohort comprised 15 942 patients with CKD (9699 [61%] women; median age, 77 years [interquartile range, 71-82]; 9707 [61%] patients started baclofen at ≥20 mg/d and 6235 [39%] at <20 mg/d). The primary outcome, hospitalization with encephalopathy, occurred in 108/9707 (1.11%) patients who started baclofen at greater than or equal to 20 mg per day and in 26/6235 (0.42%) who started baclofen at less than 20 mg per day; weighted RR, 3.54 (95% CI, 2.24 to 5.59); weighted RD, 0.80% (95% CI, 0.55% to 1.04%). In subgroup analysis, the absolute risk increased progressively at lower eGFR (weighted RD eGFR 45-59, 0.42% [95% CI, 0.19%-0.64%]; eGFR 30-44, 1.23% [95% CI, 0.62%-1.84%]; eGFR <30, 2.90% [95% CI, 1.30%-4.49%]; P for interaction, <.001]). In the secondary comparison with 284 263 nonusers, both groups of baclofen users had a higher risk of encephalopathy (<20 mg/d weighted RR, 5.90 [95% CI, 3.59 to 9.70] and ≥20 mg/d weighted RR, 19.8 [95% CI, 14.0 to 28.0]).

CONCLUSIONS AND RELEVANCE: Among older patients with CKD who were newly prescribed baclofen, the 30-day incidence of encephalopathy was increased among those prescribed higher doses compared with lower doses. If verified, these risks should be balanced against the benefits of baclofen use.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Muanda FT, Weir MA, Bathini L, et al. Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. JAMA. 2019. PMID: 31705755. doi:10.1001/jama.2019.17725

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。